/LC.GIF&client=easterncarolinaedu)
Molecular approach to cancer management / Gajanan V. Sherbet, Newcastle University, Newcastle upon Tyne, United Kingdom, The Institute for Molecular. Medicine, Huntington Beach, CA, United States.
| Author/creator | Sherbet, G. V. |
| Format | Electronic |
| Publication Info | London : Elsevier/Academic Press, [2017]. |
| Description | xxi, 329 pages : illustrations ; 24 cm |
| Supplemental Content | Full text available from eBook - Biomedical Science and Medicine 2017 [EBCBSM17] |
| Subjects |
| Contents | Modulation of growth factor signalling in targeted therapy -- The TGF-ss family accessory type III receptor function in cancer progression -- Insulin-like growth factor signalling as a target to control tumour progression -- Angiogenisis in neoplasia and anti-angiogenesis strategy in the control of tumour growth and metastasis -- On the trail of TRAIL (TNF-related apoptosis inducing ligand) in tumour growth and angiogenesis -- Hedgehog (Hh) signalling in EMT (Epithelial Mesenchyme Transition), CSCs (Cancer Stem Cells) and angiogenesis -- Hippo signalling in cell proliferation, migration and angiogenesis -- Notch signalling in carcinogenesis -- Canonical and non-canonical activation of NF-kB in tumorigenesis -- Tumour suppression and inhibition of angiogenesis by TXNIP (Thioredoxin Interacting protein) -- Cyclooxygenase-2 inhibitors suppress EMT, CSCs and angiogenesis -- Endogenous inhibitors of angiogenesis -- Stem cells in cancer therapy -- Inhibitor of DNA-binding proteins in angiogenesis -- Small molecule inhibitors of angiogenesis and cell proliferation -- Suramin and polysulphonated napthylureas as angiogenesis inhibitors -- The anti-cancer potential of flavonoids -- Selenoproteins in cancer control -- Control of tumour growth and angiogenesis by thalidomide and its analogues -- Metaformin and its anti-tumour attributes -- Statins in cancer biology -- Are there gains to be made in exploring anthrax lethal toxin (LeTx) as a tumour and an angiogenesis inhibitor? -- The HMG (High Mobility Group) proteins in cancer progression -- MTAs in EMT activation and tumour and metastasis promotion -- S100A4 has potential benefits as a therapeutic target -- Notable approaches to cancer immunotherapy. |
| Bibliography note | Includes bibliographical references and index. |
| Access restriction | Available only to authorized users. |
| Technical details | Mode of access: World Wide Web |
| Genre/form | Electronic books. |
| LCCN | 2017939040 |
| ISBN | 9780128128961 (pbk) |
| ISBN | 0128128968 (pbk) |
Availability
| Library | Location | Call Number | Status | Item Actions |
|---|---|---|---|---|
| Electronic Resources | Access Content Online | ✔ Available |